CHD2 NMD Exon Targeting in Patient and CRISPR-generated Cell Lines.

    Project: Research project

    Project Details


    CHD2 NMD exon targeting in patient and CRISPR generated cell lines. The initial proof of principle experiments is to establish whether targeting an NMD-inducing exon can restore CHD2 protein expression in haploinsufficient lines to levels similar to those in control individuals.
    Effective start/end date9/5/199/5/20


    • Stoke Therapeutics, Inc. (Agmt 9/5/19)


    Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.